The Committee for Medical Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has recommended Tessie® (tasipimidine) for marketing authorisation in the European Union.
The compound is indicated for short term alleviation of situational anxiety and fear in dogs triggered by noise or owner departure. The final decision of the European Commission on the marketing authorisation is expected in the coming months.
Tasipimidine is a new active substance, a potent and selective alpha-2A adrenoceptor agonist that inhibits the release of noradrenaline from noradrenergic neurons, blocks the startle reflex and thus counteracts arousal.
Niclas Lindstedt, Vice President, Orion Animal Health, Orion Corporation
tel. +358 10 426 4116
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.